Bli medlem
Bli medlem

Du är här

2015-03-25

Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid® in people with type 1 and type 2 diabetes

Bagsværd, Denmark, 25 March 2015 -
Novo Nordisk today announced headline results from the final phase 3a trials
for faster-acting insulin aspart, onset®1 and onset®2. The trials
investigated the efficacy and safety of faster-acting insulin aspart compared
with NovoRapid®(insulin aspart) in a basal-bolus regimen in people with type
1 and type 2 diabetes, respectively.

For further information

---------------------------------------------------------------------
| Media: |
| Mike Rulis +45 3079 3573 mike@novonordisk.com |
| Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com |
| Investors: |
| Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com |
| Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com |
| Daniel Bohsen +45 3079 6376 dabo@novonordisk.com |
| Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com |
---------------------------------------------------------------------
Company Announcement No 22 2015

Company Announcement No 22 2015
http://hugin.info/2013/R/1906174/678581.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#1906174

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.